Close Menu

CHICAGO (GenomeWeb) – Grail this week shared new data from its CCGA (Circulating Cell-free Genome Atlas) study, an exploratory effort intended to define blood-based molecular signatures that distinguish early cancers from normal control subjects.

The company presented the new data at the American Society for Clinical Oncology annual meeting here, continuing to pave the way for the clinical cancer screening tests it intends to develop.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.